Pharmaceutical

STAT+: Instead of credible data, PDS Biotech delivers ‘...

PDS Biotech's disclosures have been opaque and confusing — and maybe on purpose,...

Black former NFL players more burdened by chronic pain ...

Julius Thomas: “It's important for people to understand that there's not a statu...

Mandy Cohen, seen as next CDC director, would bring pol...

The CDC may be about to undergo a paradigm shift with the anticipated appointmen...

Opinion: STAT+: How I’m helping companies think through...

Employers and employees could fall into opposing camps, with workers demanding t...

Opinion: What happens when patients beat their doctors ...

Have you ever received test results in your email and found yourself panic-Googl...

Confo Therapeutics and AbCellera partner on GPCR-target...

Confo Therapeutics’s technology stabilises the selected GPCRs in their disease-r...

Streamlining healthcare with AI for drug development

Healthcare R&D teams are increasingly using AI for drug development. Learn more ...

How using AI in clinical trials accelerates drug develo...

The use of AI in clinical trials is improving pharmaceutical R&D, speeding up ti...

The potential of AI in pharma R&D

Developing a new drug is a monumental achievement — the reward of years of resea...

FDA accepts Ipsen’s sNDA for mPDAC therapy

The sNDA was submitted based on data obtained from the Phase III NAPOLI 3 trial.

FDA approves Amneal’s 505(b)(2) NDA for PEMRYDI RTU

PEMRYDI RTU is the first and only ready-to-use presentation of pemetrexed for in...

Sandoz targets barriers to biosimilar accessibility wit...

The company hopes to work with stakeholders to improve access to biosimilars acr...

Eloxx repackages ELX-02 data in cystic fibrosis as it e...

Eloxx reanalysed data from a Phase II trial that previously missed its efficacy ...

Astellas and Cullgen to develop small molecule protein ...

Cullgen received a $35m upfront payment and is eligible for several milestone-ba...

Verve Therapeutics and Lilly partner to advance gene ed...

Lilly will work on the development, manufacture and commercialisation activities...

STAT+: Federal advisory group rejects proposal to make ...

“It’s a setback in patient safety and surveillance,” one expert said, "and will ...